Defensin Peptides vs Exosome Skincare: A Comparison with Elevai Cell Zero Exosomes™
Both defensin-based and exosome-based technologies are positioned around skin regeneration, but they represent fundamentally different approaches — one uses two defined synthetic peptides with published mechanisms, the other uses a complex biological mixture whose active components are not individually characterized.
Exosomes are nano-sized vesicles — tiny particles secreted by cells — that carry proteins, lipids, and genetic material between cells as part of natural cellular communication. In skincare, exosome products typically use conditioned media or isolated exosomes derived from stem cells, with the premise that these vesicles can communicate regenerative signals to skin cells when applied topically.
Exosome skincare is an active and genuinely interesting area of research. However, it is also an early-stage category: the FDA has noted that no exosome products are currently FDA-approved, and the published product-specific clinical evidence base for most exosome skincare brands is limited compared to more established technologies. Understanding what is actually in an exosome product — and what the published evidence supports — is important context for any comparison.
Both defensin peptides and exosome-based products are positioned around regenerative skincare. So what actually separates them at the science level?
Elevai Cell Zero Exosomes™ are built around conditioned media from human umbilical cord mesenchymal stem cells. The primary ingredient in Elevai's Enfinity™ at-home serum is Human Umbilical Mesenchymal Stem Cell Conditioned Media — the liquid that remains after stem cells are cultured in a laboratory. This contains exosomes, but also all other proteins, lipids, and byproducts the cells secreted during manufacturing. Elevai's published product-specific evidence includes a 29-person company-sponsored study announced via press release, with peer-reviewed publication pending at time of writing.
DefenAge Age-Repair Defensins® are built around two defined, lab-synthesized peptides. Alpha-Defensin 5 and Beta-Defensin 3 are bioidentical versions of molecules the human body naturally produces — fully synthetic, vegan, and free from any biological tissue. Their mechanisms are published in peer-reviewed journals with named receptors and defined pathways. Four published peer-reviewed clinical studies document visible improvements across the face, eye area, body, and post-procedure contexts.
Both defensin-based and exosome-based technologies are areas of active research, and each approach continues to evolve as more product-specific data becomes available. The meaningful distinction at this point in time is the depth of published product-specific evidence and the degree to which the active molecules and their mechanisms have been characterized in peer-reviewed research.
Exosome-based products may appeal to users interested in emerging regenerative technologies or those following physician-guided post-procedure protocols where exosomes are being used alongside energy devices or microneedling.
For foundational context on how defensin peptides differ from retinoid-based approaches, see Defensin Peptides vs Retinol — the starting point for understanding the defensin difference.
Elevai's exosome product is positioned around regenerative cell signaling and contains a broad mixture of proteins, growth factors, and other biological material from stem cell culture. Its product-specific published clinical evidence at time of writing consists of one company-sponsored 29-person study announced via press release. DefenAge has four published peer-reviewed studies across three journals — including a multi-center, double-blind, vehicle-controlled trial (Taub et al, JDD 2018) — with defined mechanisms for each active peptide.
The core distinction is molecular definition and evidence depth. DefenAge can answer the question "which specific molecule produces which specific outcome, at what dose, through which pathway" with published citations. For Elevai's conditioned media, that question has not yet been fully characterized in published product-specific peer-reviewed research.
Two patented, lab-synthesized bioidentical peptides — Alpha-Defensin 5 and Beta-Defensin 3. Fully synthetic, vegan, no human- or animal-derived material. Defined mechanisms published in peer-reviewed journals. Four published clinical studies. Exclusive to DefenAge — no other brand can legally formulate with these molecules.
Conditioned media from human umbilical cord mesenchymal stem cells — the culture broth containing exosomes plus all other secreted proteins, lipids, and byproducts. Enfinity™ ($299, at-home) and Empower™ ($1,192, in-office). One company-sponsored 29-person study announced via press release; peer-reviewed publication pending at time of writing.
The Published Clinical Evidence — Study by Study
Understanding the evidence base for each technology is the most important part of this comparison.
Multi-center, double-blind, vehicle-controlled trial
Participants using the DefenAge defensin regimen demonstrated statistically significant visible improvement in tone, texture, firmness, lines, and overall appearance versus vehicle control. Evaluation included clinical grading, histopathology, immunohistochemistry, photography, and ultrasound.
JDD 2018;17(4):426–441. PMID: 29601620
Periocular wrinkles — independent follow-up trial
An independent follow-up trial in which participants demonstrated significant visible improvement in periocular wrinkles with the enhanced-concentration defensin BioSerum versus control — replicating the 2018 findings in an independent study.
JDD 2023;22(9):874–880. PMID: 37683059
Eye cream trial — periocular rhytids
Published trial of the DefenAge 3D Eye Radiance Cream documenting visible improvement in periocular wrinkles and skin quality in study participants.
J Cosmet Dermatol. 2020;19(8):2000–2005. doi: 10.1111/jocd.13424. PMID: 32614135
Body cream trial — skin composition
Published trial of the DefenAge 10 Luxe Hand and Body Cream documenting visible improvement in skin composition and quality — extending defensin clinical evidence to body skin.
J Cosmet Dermatol. 2023;22(2):620–627. doi: 10.1111/jocd.15118. PMID: 35621235
Microneedling with defensins vs microneedling with PRP — a published comparison
In this published pilot study, participants in the microneedling combined with defensins group demonstrated greater visible improvement in that study setting compared to participants in the microneedling combined with PRP. PRP is a platelet-derived biologic in the same general category as stem cell-derived conditioned media. This published comparison is directly relevant for anyone evaluating synthetic vs biologic-derived post-procedure options.
Facial Plast Surg Clin North Am. 2018;26(4):447–454. doi: 10.1016/j.fsc.2018.06.006. PMID: 30213426
Elevai's product-specific clinical evidence at time of writing: One company-sponsored study involving 29 participants over 12 weeks, with results announced via press release in August 2024; peer-reviewed publication was pending at time of writing. A proteomics study by Dalhousie University identified 800+ proteins in the conditioned media by mass spectrometry — this characterizes what is present in the product, but does not establish which specific components produce which clinical outcomes. Elevai references "over 1,000 clinical studies" on its marketing materials; this refers to the broader scientific literature on exosomes across all fields, not to product-specific studies on Elevai's formulation.
Defensins are also compared to other biological and growth factor-based technologies, including SkinMedica TNS® growth factors and TriHex Technology® (ALASTIN) — each representing a different approach to regenerative skincare.
Key Differences at a Glance
| Category | DefenAge Age-Repair Defensins® | Elevai Cell Zero Exosomes™ |
|---|---|---|
| Active ingredient type | Two defined, named, patented synthetic peptides with published mechanisms | Conditioned media from human umbilical cord stem cell culture — a complex biological mixture containing exosomes and other secreted material |
| Ingredient origin | Fully synthetic, vegan, no human- or animal-derived material | Human umbilical cord mesenchymal stem cell derived — human tissue origin |
| Molecular definition | Named molecules, named receptors, published dose-response pathways | 800+ proteins identified by proteomics — which specific components produce which outcomes has not been established in published product-specific research |
| Published clinical trials | Four published peer-reviewed studies across three journals — face, eyes, body, post-procedure | One company-sponsored 29-person study announced via press release (2024); peer-reviewed publication pending at time of writing |
| Study methodology | Multi-center, double-blind, vehicle-controlled (Taub 2018) with histopathology and ultrasound | Company-sponsored study design; peer-reviewed methodology not yet available at time of writing |
| Batch consistency | Identical batch to batch — synthetic peptides with fixed sequences and concentrations | Biological variability is inherent in tissue-derived conditioned media; peer-reviewed literature documents batch-to-batch variability in exosome products from biological sources |
| Regulatory context | Cosmetic classification — not a biologic, drug, or human tissue product | Marketed as cosmetic; FDA has issued guidance that no exosome products are currently FDA-approved — an evolving regulatory area for the exosome category broadly |
| Price | $198 (8-in-1 BioSerum) | Enfinity™ $299 (at-home); Empower™ $1,192 (in-office) |
Four Meaningful Differences Worth Understanding
Conditioned media is not the same as purified exosomes
Elevai's Enfinity™ lists its primary active ingredient as Human Umbilical Mesenchymal Stem Cell Conditioned Media — not isolated exosome vesicles. Conditioned media is the complete liquid that remains after stem cells are cultured: it contains exosomes, but also every other protein, metabolite, and cellular byproduct the cells secreted during manufacturing. DefenAge's defensin peptides are the molecule itself — synthesized to exact structure with no biological broth, no undefined fractions.
Knowing what is present is not the same as knowing what works
Elevai references a Dalhousie University proteomics study identifying 800+ proteins in its conditioned media. This characterizes what is in the product. It does not establish which of those 800+ components produces which visible outcome — or at what concentration. DefenAge's clinical evidence answers that question directly: which peptide, which receptor, which pathway, at what dose, with what published outcome. Cataloging is not mechanism.
Product evidence vs category evidence
Elevai's marketing references "over 1,000 clinical studies." This refers to the broader scientific literature on exosomes across all research fields — not to studies on Elevai's specific product. The distinction matters: a vitamin C serum could reference thousands of studies on vitamin C; that does not make them product studies. DefenAge's four published studies are all product-specific — conducted on DefenAge formulations, with DefenAge subjects, producing DefenAge-specific results with PMIDs.
Synthetic consistency vs biological variability
DefenAge's synthetic peptides are identical batch to batch — same molecules, same concentrations, year after year. Conditioned media from biological sources is inherently variable: its composition depends on cell culture conditions, passage number, nutrient media, and processing. Peer-reviewed literature documents batch-to-batch variability in exosome products from biological sources, even with standardized manufacturing. For consumers who want predictable, consistent results, synthetic definition matters.
About Exosome Skincare — What the Current Evidence Shows
Exosome science is genuinely interesting and the field is moving quickly. Exosomes play real roles in cellular communication, and there is legitimate scientific interest in whether topically applied exosomes from stem cell sources can influence skin biology.
However, for consumers evaluating exosome skincare products today, a few context points are worth understanding clearly:
The FDA has stated that no exosome products are currently FDA-approved. The agency has issued warning letters to companies making unapproved claims about exosome products in other medical contexts. For topical cosmetic products, the regulatory picture is evolving.
The distinction between conditioned media and purified exosomes is meaningful. Many products marketed as "exosome" skincare contain conditioned media — the whole culture broth — not isolated and characterized exosome vesicles. These are different things with different purity profiles.
This does not mean exosome skincare does not work — it means the product-specific published evidence base is still developing. DefenAge's defensin technology has a more established peer-reviewed evidence base for its specific products than exosome skincare brands currently do. As the exosome field matures and more product-specific peer-reviewed trials are published, that picture may change.
DefenAge may be right for you if:
- You want clinically studied visible improvement with four published peer-reviewed studies
- You want fully synthetic, vegan ingredients with no human- or animal-derived material
- You want a technology whose active molecules and mechanisms are fully defined and published
- You want batch-consistent results from a defined synthetic formula
- You want a patented molecule exclusive to one brand — technology no other brand can replicate
- You prefer a more established published evidence base before adopting a new technology
Exosome skincare may appeal to you if:
- You are interested in emerging regenerative technologies and comfortable being an early adopter
- Your dermatologist has recommended exosome products as part of a specific post-procedure protocol
- You are interested in the cell-signaling approach to skin renewal and want to follow the science as it develops
- You are aware of the current limitations of the published evidence base and are making an informed choice
Exosome skincare is a genuinely interesting category, and the science behind cellular communication via exosomes is real. However, for a consumer choosing between these two technologies today, the published evidence base is not comparable. DefenAge has four published peer-reviewed studies with defined mechanisms, named molecules, and verifiable PMIDs. Elevai's product-specific peer-reviewed evidence at time of writing consists of one company-sponsored study with results announced via press release.
DefenAge's defensin peptides are also fully synthetic and vegan — no human tissue, no biological variability, no conditioned media. For consumers who want established peer-reviewed clinical evidence, defined molecular mechanisms, and fully synthetic ingredients — DefenAge's published evidence base is meaningfully more developed than the current product-specific evidence for exosome skincare.
What Dermatologists Have Said About Defensin Technology
"The science is remarkable. For patients who previously couldn't tolerate retinoids, the visible results I've seen with defensin technology have been genuinely impressive."
Amy Taub, MD Lead author, Taub et al JDD 2018; co-investigator, Hartman et al JDD 2023
"For patients with sensitive skin or rosacea who need effective anti-aging without retinol irritation, this is the alternative I reach for. It delivers visible results without the trade-offs."
Melda Isaac, MD Board-Certified Dermatologist, Washington DC
"Defensins represent a new era in skin rejuvenation. The approach is genuinely distinct from growth factors, retinoids, and standard peptide categories — it belongs in its own class."
Gregory Keller, MD Principal Investigator, Taub et al 2018; Berens et al 2020; Eggerstedt et al 2023
Frequently Asked Questions
Is DefenAge the same as exosome skincare?
No — they are fundamentally different approaches. DefenAge uses two defined, lab-synthesized bioidentical peptides with published mechanisms, peer-reviewed clinical evidence, and fully synthetic ingredients. Exosome skincare like Elevai uses conditioned media from stem cell culture — a complex biological mixture containing exosomes alongside many other secreted proteins and byproducts. The molecules are different, the evidence bases are different, and the ingredient origins are different.
What is "conditioned media" — and is it the same as exosomes?
No — conditioned media and isolated exosomes are different things. Conditioned media is the complete liquid that remains after cells are grown in a laboratory: it contains exosomes, but also all other proteins, metabolites, lipids, and cellular byproducts the cells secreted during culture. Isolated exosome products involve additional purification steps to concentrate the exosome fraction specifically. Elevai's Enfinity™ lists Human Umbilical Mesenchymal Stem Cell Conditioned Media as its primary active ingredient — this is conditioned media, not isolated exosome vesicles.
What does Elevai mean by "over 1,000 clinical studies"?
This refers to the broader scientific literature on exosomes across all research fields — not to clinical studies on Elevai's specific product. Exosome biology has been studied extensively in many medical contexts. Elevai's product-specific published clinical evidence at time of writing consists of one company-sponsored 29-person study announced via press release, with peer-reviewed publication pending. The distinction between field literature and product-specific evidence is important when evaluating any skincare brand's evidence claims.
Are exosome skincare products FDA approved?
No. The FDA has stated that no exosome products are currently FDA-approved. The agency has issued guidance and warning letters to companies making unapproved claims about exosome products in various medical contexts. Topical exosome cosmetic products occupy an evolving regulatory space. DefenAge's defensin peptides are cosmetic ingredients with a straightforward regulatory classification — not biologics, drugs, or human tissue products.
Can I use DefenAge after microneedling or laser treatments?
Yes — DefenAge has published post-procedure evidence. In a published pilot study (Duncan, Facial Plastic Surgery Clinics of North America, 2018), participants in the microneedling combined with defensins group demonstrated greater visible improvement in that study setting than participants in the microneedling combined with PRP group. PRP is a platelet-derived biologic in the same general category as stem cell-derived conditioned media. DefenAge is used by dermatologists in post-procedure protocols as a fully synthetic, vegan alternative to biologic-based post-procedure products.
How does DefenAge compare to exosome skincare on price?
DefenAge's 8-in-1 BioSerum is $198. Elevai's at-home Enfinity™ serum is $299, and their in-office Empower™ treatment is $1,192. DefenAge is priced lower than both Elevai products while having a more developed product-specific peer-reviewed evidence base. DefenAge is also priced below several other medical-grade skincare peers including SkinMedica TNS Advanced+ (~$295) and Augustinus Bader (~$300).
Will exosome skincare improve as the science develops?
Possibly — and this is worth acknowledging honestly. Exosome science is an active research area and product-specific clinical evidence may grow considerably as the field matures. The comparisons on this page reflect the published evidence available at time of writing. DefenAge's position is based on its own published peer-reviewed evidence, not on a permanent judgment about the exosome category. Consumers who are interested in exosome skincare and want to follow the science as it develops should look for peer-reviewed product-specific publications rather than field literature citations when evaluating any brand's evidence claims.
Explore more comparisons
References & Further Reading
- Taub A, Bucay V, Keller G, Williams J, Mehregan D. "Multi-Center, Double-Blind, Vehicle-Controlled Clinical Trial of an Alpha and Beta Defensin-Containing Anti-Aging Skin Care Regimen." Journal of Drugs in Dermatology. 2018;17(4):426–441. PMID: 29601620
- Hartman N, Loyal J, Taub A, Fabi S. "Clinical Trial of Alpha and Beta Defensin Skin Care Regimen for Improvement of Periocular Wrinkles." Journal of Drugs in Dermatology. 2023;22(9):874–880. doi: 10.36849/JDD.7184. PMID: 37683059
- Berens AM, Ghazizadeh S. "Effect of defensins-containing eye cream on periocular rhytids and skin quality." Journal of Cosmetic Dermatology. 2020;19(8):2000–2005. doi: 10.1111/jocd.13424. PMID: 32614135
- Eggerstedt M, Torres-Maldonado S, Danielian A, Hwang SHJ, Echanique KA. "Impact of defensins-containing body cream on skin composition." Journal of Cosmetic Dermatology. 2023;22(2):620–627. doi: 10.1111/jocd.15118. PMID: 35621235. PMCID: PMC10087582
- Duncan DI. "Microneedling with Biologicals: Advantages and Limitations." Facial Plastic Surgery Clinics of North America. 2018;26(4):447–454. doi: 10.1016/j.fsc.2018.06.006. PMID: 30213426
- Takahashi M, Umehara Y, Yue H, et al. "The Antimicrobial Peptide Human β-Defensin-3 Accelerates Wound Healing by Promoting Angiogenesis, Cell Migration, and Proliferation Through the FGFR/JAK2/STAT3 Signaling Pathway." Frontiers in Immunology. 2021;12:712781. doi: 10.3389/fimmu.2021.712781
- Shimizu Y, Nakamura K, Kikuchi M, et al. "Lower human defensin 5 in elderly people compared to middle-aged." GeroScience. 2022;44(2):997–1009. PMID: 34105106
- Grove GL, Kligman AM. "Age-associated changes in human epidermal cell renewal." Journal of Gerontology. 1983;38:137–142.
- DefenAge. "Peer-reviewed study confirming effectiveness of defensin-based BioSerum." View study summary
- DefenAge. "Physician testimonials and clinical perspectives." View testimonials
DefenAge products are cosmetic formulations intended to improve the appearance of the skin and are not intended to affect the structure or function of the body. This page is for cosmetic skincare education only and does not constitute medical advice. Physician quotes are sourced from publicly available DefenAge materials and used with permission. Cell Zero Exosomes™, Empower™, and Enfinity™ are trademarks of Elevai Skincare Inc. — referenced here for comparison purposes only. Age-Repair Defensins® and DefenAge® are trademarks of Progenitor Biologics, LLC. Product prices are approximate and subject to change. Technology comparisons are based on publicly available ingredient information, published peer-reviewed literature, and manufacturer materials at time of publication. DefenAge makes no claims regarding the efficacy of competitor technologies.